Literatur
Supady A, Brodie D, Wengenmayer T (2022) Extracorporeal haemoadsorption: does the evidence support its routine use in critical care? Lancet Respir Med 10:307–312
Gruda MC, Ruggeberg KG, O’sullivan P et al (2018) Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(R) sorbent porous polymer beads. PLoS One 13:e191676
Jansen A, Waalders NJB, Van Lier DPT et al (2023) CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care 27:117
Eichhorn T, Rauscher S, Hammer C et al (2016) Polystyrene-Divinylbenzene-based adsorbents reduce Endothelial activation and monocyte adhesion under septic conditions in a pore size-dependent manner. Inflammation 39:1737–1746
Poli EC, Rimmele T, Schneider AG (2019) Hemoadsorption with CytoSorb((R)). Intensive Care Med 45:236–239
Millar JE, Fanning JP, Mcdonald CI et al (2016) The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care 20:387
Adrie C, Adib-Conquy M, Laurent I et al (2002) Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106:562–568
Supady A, Zahn T, Kuhl M et al (2022) Cytokine adsorption in patients with post-cardiac arrest syndrome after extracorporeal cardiopulmonary resuscitation (CYTER)—A single-centre, open-label, randomised, controlled trial. Resuscitation 173:169–178
Akin M, Garcheva V, Sieweke JT et al (2020) Early use of hemoadsorption in patients after out-of hospital cardiac arrest—a matched pair analysis. PLoS ONE 15:e241709
Monard C, Bianchi N, Poli E et al (2023) Cytokine hemoadsorption with CytoSorb(®) in post-cardiac arrest syndrome, a pilot randomized controlled trial. Crit Care 27:36
Supady A, Weber E, Rieder M et al (2021) Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med 9:755–762
Supady A (2021) Cytokine adsorption and ECMO in patients with COVID-19—Author’s reply. Lancet Respir Med 9:e72–e74
Hayanga JWA, Song T, Durham L et al (2023) Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Crit Care 27:243
Supady A, Staudacher DL, Wengenmayer T (2023) Comment on: Extracorporeal hemoadsorption in critically ill COVID‑19 patients on VV ECMO: the CytoSorb therapy in COVID‑19 (CTC) registry. Crit Care 27:297. https://doi.org/10.1186/s13054-023-04578-4
Becker S, Lang H, Vollmer Barbosa C et al (2023) Efficacy of CytoSorb(R): a systematic review and meta-analysis. Crit Care 27:215
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Supady erklärt, dass er Vortragshonorare und Forschungsförderung von CytoSorbents, dem Hersteller des CytoSorb Adsorbers erhalten hat. Weitere potenzielle Interessenkonflikte liegen nicht vor.
Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
Michael Buerke, Siegen
Dieser Artikel basiert auf der Habilitationsschrift über Zytokinadsorption bei extrakorporaler Membranoxygenierung, aufgrund der der Autor am 23.02.2023 von der Albert‑Ludwigs‑Universität Freiburg für das Fach Innere Medizin habilitiert wurde.
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Supady, A. Zytokinadsorption bei extrakorporaler Membranoxygenierung. Med Klin Intensivmed Notfmed 118, 499–501 (2023). https://doi.org/10.1007/s00063-023-01058-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00063-023-01058-z